The Lyme Disease Project
October 9, 2016

Introduction
We were first asked to find a treatment for Lyme disease in the fall of 2016. The client wanted us to find a way to quickly treat the disease (because in some patients antibiotic treatments are not effective or can take many months), and more importantly find a way to eliminate persistent chronic symptoms that do not respond to antibiotic treatment in some patients.

Cause and diagnosis
As Wikipedia notes, Lyme's disease is caused by a spirochetes bacteria from the genus Borrelia. The disease is carried by a tick, and about 30,000 new cases every year are reported to the CDC (Center for Disease Control) in the USA alone. Often the initial infection site can be seen on the skin, but the main problem with this disease is that the symptoms can vary quite widely, making initial diagnosis difficult. Although one can do antibody tests for the disease, this is only considered reliable in the later stages of the disease, after sufficient immune response in the patient has occurred.

Chronic symptoms and controversy
Again from Wikipedia, "Up to one third of Lyme disease patients who have completed a course of antibiotic treatment continue to have symptoms, often termed 'post-Lyme syndrome', such as severe fatigue, sleep disturbance, unconsciousness, and cognitive difficulties, with these symptoms being severe in about 2% of cases. While it is undisputed these patients can have severe symptoms, the cause and appropriate treatment is controversial."

Applying subcellular psychobiology to a bacterial disease
From the Institute's perspective, this was an interesting project because the cause of the disease was already known (unlike most of our research projects). Thus, from a time perspective, a large part of the investigative work was already done for us since we did not also need to figure out the originating disease. From a verification and testing perspective, it would allow us to use standard laboratory diagnostic techniques (besides symptom elimination) to check the effectiveness of any treatments we developed. From a public health perspective, it would also demonstrate an application of subcellular psychobiology as a complement / alternative to both conventional drug treatments (in this case antibiotics) and as a potential immunization procedure (like a vaccine). As antibiotics are becoming more and more ineffective, the need to find an alternative to antibiotics is becoming more and more pressing worldwide, making this an interesting test case for our work.

Our initial research findings
In October of 2016, based on just work with just one individual (N=1), we were able to investigate the cause of the disease and come up with a potential treatment. However, please understand - until we test with many more people we won't know if this experimental treatment will work on other people, nor do we know if long term symptoms will be eliminated. Only more testing with many people will be able to determine this. You are simply getting a snapshot of the research phase of the investigation, which if we are unlucky can drag on for years.

In our investigation, we found the spirochetes in the tissues of the body of the client, as one would expect. However, there was immediately another aspect to the disease that was a surprise. The spirochetes appeared to give off a black liquid that was highly addictive to the client. Checking, we found that the spirochetes with their black liquid were also found inside the primary cell of the client. (That the spirochetes can live inside cells is known, and it is suspected that this can make it harder to cure the disease as it gives another place for the spirochetes to 'hide' from antibiotic treatments.)

A psychoneuroimmunology principle
One of the key discoveries of the subcellular psychobiology approach to disease treatment is that the body of the patient is actually actively and deliberately keeping the disease. Although from a logical perspective this makes absolutely no sense, from a psychobiology perspective there is always a reason why the patient wants the disease, even though the effect of the disease can be harmful or even deadly to them. To put it another way, from a body perspective there is 'motive and opportunity'. The 'motive' is usually a generational identity problem ("this is just how my family is or should be") or a developmental problem that left a symptom that the client's body wants to cover up or reduce. The 'opportunity' part of this is the initial exposure to a disease that gives them what their body feels it needs to suppress their underlying issue. Unfortunately, disease organisms have an agenda of their own, so the initial relief soon morphs into a nightmare for the person as the disease proceeds to harm the client. From the body perspective, it becomes a balancing act between the desire for relief from their underlying developmental problem versus the pain they get from the damage that the disease inflicts. Hence, this unconscious dilemma drives the chronic nature of some diseases. (Note that there are other mechanisms for disease not covered here - this one is just very common in chronic illness and turns out to apply to Lyme disease.)

The developmental origin of the susceptibility to Lyme disease
We were very fortunate to quickly find the feeling that the client wanted to cover up with the Lyme disease. Thus, even though the disease itself did not appear until he was bit by a tick, the feelings he wanted the tick disease to cover up were coming from a specific and unusual implantation problem. This traumatic implantation issue itself was in turn caused by a fungal disease that the zygote was carrying. From here, we were able to find that the initial infection by this fungus was in the sperm from very early in its development. Thus, potential treatments could be done either at implantation, or inside the testes of the father. For our test client, we chose to find and use a treatment that eliminated the initial fungal infection in the sperm. This appeared to work successfully - eliminating this sperm fungus in turn eliminated the spirochetes from both the tissues of the client as well as from inside the primary cell itself.

A treatment for chronic symptoms?
Will this approach work on people who have chronic symptoms? We have no idea yet - this needs to be tested. Unfortunately, there are several issues here that potentially could make treatment unsuccessful in some people. First, it is not even clear that Lyme disease is causing some of the symptoms that these chronic sufferers have. We're looking at a huge population that have or had the disease, and it stands to reason in such a large group there are people with multiple and unrelated diseases. Secondly, the symptoms may be caused by secondary damage to the host that simple elimination of the spirochetes will not treat. However, if a given client has chronic symptoms that are due to the Lyme disease, experience working with other diseases has shown us that there is a good chance that chronic symptoms will also be eliminated or reduced. Only testing will tell.

Proactive immunization
As mentioned earlier, one of the applications of the subcellular psychobiology approach is that, once a reliable treatment is developed, it can be used proactively. In other words, it can be used as an immunization technique before a person is exposed to infected ticks. The huge advantage here is that the cost is minimal, and for many people might even be able to be done via a YouTube tutorial. This is one of the more exciting applications of this new technology, particularly in view of third world medical applications where money and trained medical personal is rare or nonexistent.


References

  • "Lyme disease" in Wikipedia
  • "Lyme disease controversy" in Wikipedia
  • "Lyme disease microbiology" in Wikipedia
  • "Epigenetics, psychoneuroimmunology, and subcellular psychobiology" (blog, 2016)
  • "Subcellular psychobiology is a 'disruptive technology'" (blog, 2016)
  • "Where are the 'medical' applications?" (blog, 2016)


Revision History
Oct 9, 2016: First description of the disease and potential treatment.